AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06260618 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelfoam
Description: GELFOAM Sterile Compressed Sponge is a medical device intended for application to bleeding surfaces as a hemostatic. It is a water-insoluble, off-white, nonelastic, porous, pliable product prepared from purified porcine skin, Gelatin USP Granules and Water for Injection, USP. It may be cut without fraying and is able to absorb and hold within its interstices, many times its weight of blood and other fluids.
Study NCT06260618 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Chitodex
Description: The Chitogel Endoscopic Sinus Surgery Kit contains components and equipment for the preparation of a nasal gel to be applied to the sinus cavities via a supplied and specifically designed malleable cannula.~The Gel preparation will take approximately 30 minutes, so preparation must start sufficiently in advance of when the Gel is expected to be used in surgery.~Once the Gel has been prepared it should be applied to the sinus cavities on both sides within six hours using the malleable cannula supplied with the Kit.~The Gel must be prepared on a sterile surface following these instructions. There are two main components to the Gel.~1. Dextran Aldehyde (B), which is a dry powder, and is reconstituted into a liquid form through mixing the powder with a liquid Sodium Phosphate Buffer (A). Both of these components are supplied sterile.~2. The second component Chitosan Succinamide (C), is a liquid and is also supplied sterile.
Study NCT04851015 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trimethoprim-sulfamethoxazole
Description: 10mg/kg/day of TMP component
Study NCT04851015 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: trimethoprim-sulfamethoxazole
Description: 15mg/kg/day of TMP component
Study NCT05460000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3 cycles chemotherapy instead of 6 cycles chemotherapy
Description: We hypothesise that recurrence free survival in patients receiving 3 cycles of chemotherapy followed by maintenance with niraparib is not inferior to 6 cycles of chemotherapy followed by niraparib in advanced HRDpositive high-grade ovarian cancer patients with no residual tumor mass following primary tumor debulking.
Study NCT05460000 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 6 cycles chemotherapy
Description: Standard chemotherapy as comparator
Study NCT05465876 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: EVUSHELD
Description: EVUSHELD is a combination of 2 monoclonal antibodies (mAbs), Tixagevimab and Cilgavimab. The single dose, is to be administered intramuscular, each mAb sequentially into the deltoid
Study NCT05067244 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MDMA
Description: MDMA assisted psychotherapy
Study NCT05994534 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cysteamine Bitartrate
Description: Single dose, tablets at current therapeutic dose
Study NCT05994534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetylcysteine Amide
Description: Single dose, oral solution
Study NCT05705128 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine will be given with bupivaciane for postoperative pain control
Study NCT06104618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab Vedotin
Description: Given IV
Study NCT05464836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CB-103
Description: Given by PO
Study NCT05464836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given by PO
Study NCT04773249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lateral Epicondylitis Bandage
Description: The lateral epicondylitis bandage was first used by Ilfeld in 1965, and it is a non-elastic band that prevents the expansion of the muscles in the proximal forearm. A lateral epicondylitis bandage will be given to the patient for 6 weeks. The bandage will be positioned 5 cm distal to the lateral epicondyle to allow for elbow flexion. After the application, patients will be asked to punch and the belt on the band will be tightened. After the patients are asked to open the fist, the suitability of the pressure applied to the forearm will be evaluated. Patients will be asked to repeat this application while wearing the band. The patients will also be asked to use the bandage throughout the day, and to remove them during bathing and sleeping.
Study NCT04773249 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wrist Extension Splint
Description: Wrist extension splint is an upper extremity orthosis that keeps the wrist at 15-20 degrees of extension with the polyethylene bar it contains. A wrist extension splint will be given to the patient for 6 weeks. The splint will be used to keep the wrist at 15-20 degrees of extension and to wrap the distal wrist and forearm without hindering finger movements. The patients will be asked to use the splint throughout the day, and to remove them during bathing and sleeping.
Study NCT04860843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thoracic paravertebral block
Description: Participants will receive a thoracic paravertebral with local anesthetic infiltrate (30ml of 0.35% ropivacaine with 1:400K epinephrine).
Study NCT04860843 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Thoracic paravertebral block
Description: Participants will receive a thoracic paravertebral with local anesthetic infiltrate (30ml of 0.35% ropivacaine with 1:400K epinephrine).
Study NCT04860843 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pecs block
Description: Participants will receive a pecs block with local anesthetic infiltrate (30ml of 0.25% ropivacaine with 1:400K epinephrine).
Study NCT04860843 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Pecs block
Description: Participants will receive a and a pecs block with saline infiltrate (30ml normal saline; 0.9% NaCl).
Study NCT05157204 — intervention group
Intervention type: PROCEDURE
Intervention: measurment of interleukin-6 at exhaled condensate
Description: the breath condensate samples were collected using a specially designed condensing chamber ( Ecoscreen; Jaeger, Hoechberg, Germany) to measure the interleukin-6 at exhaled condensate of 60 participants
Study NCT06557551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thin catheter surfactant
Description: Surfactant given through thin catheter inserted under video laryngoscopy at or after 5 minutes of life
Study NCT05733585 — intervention group
Intervention type: DEVICE
Intervention: Purabond
Description: hemostatic efficacy of PuraBond
Study NCT05701384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lazertinib
Description: 160mg po qd
Study NCT05781490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lumentin® 44 Powder for oral foam
Description: Lumentin® 44 is a foam for oral use.
Study NCT05721339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: ACT will be applied through 8 sessions by the psychological flexibility processes, which were grouped into three response styles: open, aware, and active. Openness is reflected by acceptance, which means the conscious embrace of psychological events without unnecessary attempts to change their frequency. Defusion means untangling unhelpful thoughts and responding to mental experiences as experiences rather than guides to action. The awareness set, which is reflected by applying self-as-context, which means a continuous and secure I from which events are experienced but distinct from those events. A present moment means ongoing, nonjudgmental contact with internal and external events as they occur in the present moment. The active set, which was reflected by making the intern nurses embrace their desired and chosen life values directions, and commit action to selected values.
Study NCT06229080 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexGel
Description: When a planned perfused area includes two or more Couinaud segments and more than 50% of the target area is non-tumorous liver, short-acting gelatin sponge particles (NexGel) will be administered to the hepatic arteries toward the non-tumorous liver. The embolization particles will be prepared by mixing one vial of the particles with 5 mL of iodinated contrast agents and intra-arterially delivered with a microcatheter 2.0-Fr or larger. After confirming the disappearance or substantial reduction of liver parenchymal staining of the embolized area on angiography, radioembolization using Y90 glass or resin microspheres will be conducted. Digital subtraction angiography will be performed 30 minutes after the transient embolization to identify recanalization of the transiently embolized hepatic arteries.
Study NCT06561555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RC48
Description: RC48 at a dosage of 2mg/kg administered intravenously every 3 weeks (ivgtt q3w) is continued until disease progression, with the allowance for treatment discontinuation due to disease progression, death, intolerable toxicity, withdrawal of informed consent, initiation of new antineoplastic therapy, or other reasons specified in the protocol, with the earliest occurring event taking precedence. Alternatively, the study investigator may determine the need to discontinue treatment.
Study NCT04995003 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: T cells or CAR T cells
Description: There are 2 dose levels:~Dose Level 1 (1x10\^8 cells/m2) and Dose Level -1 (5x10\^7 cells/m2). In the event that Dose Level 1 is not tolerable, de-escalation to Dose Level -1 will occur.
Study NCT04995003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab Injectable Product
Description: 2 mg/kg/dose (max 200 mg/dose) every 3 weeks
Study NCT04995003 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab Injectable Product
Description: 3 mg/kg/dose (\<40kg) or 124 mg (≥40 kg) every 2 weeks
Study NCT06147401 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PENG plus LFCN block
Description: The experimental arm will be subjected to a combination of peripheral blocks: the interfascial block of the PENG and the perinervous block of the LFCN~The PENG block involves deposition of local anesthetic in the fascial plane between the psoas muscle and the superior pubic ramus.~The LFCN block consists of applying local anesthetic near the nerve. The LFCN lies in the subcutaneous plane deep to the fascia lata below the anterior superior ischiatic spine.
Study NCT05452512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Self monitoring
Description: Self monitoring using smart clinical trial application
Study NCT05452512 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Self monitoring
Description: Self monitoring using smart clinical trial application
Study NCT05452512 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Smart watch assisted monitoring
Description: Smart watch-assisted adherence monitoring
Study NCT06438367 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C]TGRX-326
Description: Healthy subjects will be given TGRX-326 60 mg orally on day 1.
Study NCT05452512 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: Vitamin D self-administration for 3 months
Study NCT05452512 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D self-administration for 3 months
Study NCT05295290 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cardiac Imaging
Description: ECG, echocardiogram, ambulatory monitor, exercise stress test
Study NCT05456841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Empathic Communication Skills (ECS) training
Description: The overall training goal of this 2.25 hour module ECS module is to enhance OCP recognition and responsiveness to lung cancer patients' empathic opportunities by communicating understanding, alleviating stigma and distress, and providing support. The ECS training also provides tools to OCPs to buffer/inoculate patients against stigmatizing attitudes and behaviors by others such that lung cancer patients who currently or formerly smoked can be given small doses of an opposing viewpoint (termed as preparing patients for recurring smoking questions) and suggestions of counterarguments in order to make them resistant to future stigmatizing attacks by others
Study NCT05456841 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care participant interaction
Description: Standard of Care participant interaction
Study NCT05376306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction: MBSR
Description: Four activities, one each week - raising body awareness, sitting meditation, mindful yoga, expanding awareness meditation.
Study NCT05376306 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Reduction : PMR
Description: Progressively tensing and releasing each muscle group from head to toe in a specific order.
Study NCT05298501 — intervention group
Intervention type: OTHER
Intervention: No intervention/exposure
Description: No interventions/exposures will be administered or evaluated
Study NCT05386836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pulse oximeter validation population
Description: Evaluation of the SpO2 accuracy performance of the Sunrise Sensor 2 placed at the tip of the chin during non-motion conditions over the range of 70-100% by comparison to SaO2 values determined from arterial blood sample specimen analyzed by a CO-oximeter.
Study NCT05359757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Effect of Naturalistic Teaching Strategies in Children with autism spectrum disorder
Description: In this group, the patients will be provided with both the naturalistic therapeutic techniques the PECS Therapy.~A baseline of the kids in this group will be made using the portage guide and PECS~* Incidental teaching trial, natural language paradigm, and time delay concepts will be incorporated in the therapy sessions and communication using picture cards will be made.~* 40 minutes session will be conducted in which 20 minutes session will be for naturalistic teaching techniques and 20 minutes will be for PECS.~* This will be followed for 30 sessions
Study NCT05359757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PECS Therapy only
Description: A baseline will be developed using the portage guide and PECS.~* Communication strategies using the PECS picture cards will be made~* 30 minutes session will be conducted~* This will be followed for 30 sessions
Study NCT06050603 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TMS
Description: The target locations of TMS will be cortical regions defined by either anatomical landmarks or functional regions derived from the individual's functional and structural MRI for Aim 1. TMS target locations for Aim 2 and 3 are determined by Aim 1's results. These TMS target regions will be guided by a navigation system.~TMS will be parametrically varied with combinations of pulse strength and frequencies based on experimental conditions. TMS strength will be referred to the resting motor threshold (rMT), which will be determined independently for each participant. TMS pulses will be delivered at fixed time instants for Aim 2 and at time instants based on the phase of oscillatory neural activity for Aim 3.
Study NCT05359757 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PECS Therapy only
Description: A baseline will be developed using the portage guide and PECS.~* Communication strategies using the PECS picture cards will be made~* 30 minutes session will be conducted~* This will be followed for 30 sessions
Study NCT04209842 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: gastric balloon
Description: non surgical weight loss via placement of gastric balloon
Study NCT04841876 — intervention group
Intervention type: OTHER
Intervention: rugby matches
Description: standard rugby-7s match
Study NCT04954443 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Removing urinary catheter
Description: Removing urinary catheter after vaginal surgery of pelvic organ prolapse
Study NCT04954443 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Removing urinary catheter
Description: Removing urinary catheter after vaginal surgery of pelvic organ prolapse
Study NCT06147401 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: FIC Block
Description: The control arm will be subjected to an interfascial block, the fascia iliaca Compartment Block.~The FICB consists in the injection of anaesthetic agents into the fascia iliaca compartment.
Study NCT04867278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: External Beam Radiation (XRT)
Description: Patients that undergo surgical fixation of an acetabular fracture will receive debridement and a single fraction of external beam radiotherapy to the surgical site within 72 hours of surgery.
Study NCT04796220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine (900 mg/m2) will be administered intravenously on day 1.
Study NCT04796220 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Focused Ultrasound
Description: Focused ultrasound will be applied to up to 2 breast lesions on day 8.
Study NCT05882721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sofwave
Description: The Sofwave System, comprised of an applicator and a console, generates high intensity, non-focused ultrasonic energy which can be delivered percutaneously to tissues.~Other Names:~SUPERB
Study NCT04796220 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Focused Ultrasound
Description: Gemcitabine (900 mg/m2) will be administered intravenously on day 1.Focused ultrasound will be applied to up to 2 breast lesions on day 8.
Study NCT04867278 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Debridement
Description: Gluteus minimus debridement in the OR
Study NCT04867278 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Debridement
Description: Gluteus minimus debridement in the OR
Study NCT05622201 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rituximab
Description: Infusion
Study NCT05622201 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Infusion
Study NCT06469359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal tissue-resident memory T and B cells
Description: Nasal tissue-resident memory T and B cells are quantified using flow cytometry.
Study NCT06559644 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hema-NeoTIL01
Description: Patients will receive intravenous infusion of Hema-NeoTIL01, which is a highly specific tumor infiltrating lymphocyte (TIL) product derived from patients' bone marrow or peripheral blood, expanded ex vivo through antigen presentation.
Study NCT06558955 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Technology-enabled anticipatory guidance and peer support
Description: The intervention includes 4 online sessions led by an oral health therapist (OHT) or dentist, as well as push notifications and information delivered to participants via a mobile/web app.
Study NCT06558955 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional health education
Description: Participants on this arm will receive conventional child oral health education materials at 4 time points.
Study NCT06185491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HGI
Description: Data collection from glucose monitoring systems and dosage of glycated hemoglobin and glycated albumin measured 3 times at 6-month intervals (+/- 3 months)
Study NCT05938010 — intervention group
Intervention type: DEVICE
Intervention: Dailies Total1® contact lenses for astigmatism (T30fA)
Description: Dailies Total1® contact lenses for astigmatism (T30fA)
Study NCT05171335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Participants will receive approximately six, 28-day cycles of lenvatinib (LENVIMA®, Eisai Inc., Woodcliff Lake, NJ). Lenvatinib will be administered at 12 mg orally once daily for patients with a body weight ≥60 kg and at 8 mg orally once daily for patients with a body weight of \<60 kg.~Administration of lenvatinib will occur at least 2 weeks before the first standard of care TACE procedure and study drug treatment will continue for 6 months. Lenvatinib will be held for 7 days before and 7 days after each TACE. Participants can receive up to 3 TACE procedures per protocol depending on their response and transplantation time.
Study NCT05171335 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transcatheter Arterial Chemoembolization
Description: Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.
Study NCT05171335 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Transcatheter Arterial Chemoembolization
Description: Traditional standard of care: Transcatheter Arterial Chemoembolization (TACE) treatment for hepatocellular carcinoma. Chemotherapeutic drug-coated particles are inserted via a catheter into an artery that supplies blood to a tumor where the drug works to cut off blood supply to the tumor.
Study NCT06469359 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal fluid sampling
Description: Nasal fluid is collected using strip (Hunt Development) in both nostrils
Study NCT04880616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NBI-827104
Description: Capsules for oral administration
Study NCT04880616 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Capsules matching NBI-827104 for oral administration